Search

Displaying results 4891 - 4900 of 7018 in total
  1. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. … IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia.

  2. Drug

    Canfosfamide

    go.drugbank.com/drugs/DB04972
    Investigational

    Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.

  3. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers … These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as

  4. Drug

    Basic Fibroblast Growth Factor

    go.drugbank.com/drugs/DB14131
    Investigational

    Basic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis. … The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages.

  5. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. … It was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain).

  6. Drug

    Pidotimod

    go.drugbank.com/drugs/DB11364
    Investigational

    Pidotimod is a synthetic dipeptide with immunomodulatory properties.[A7956]

  7. Drug

    ATR-04

    go.drugbank.com/drugs/DB26782
    Investigational

    ATR-04 is a biologic drug. ATR-04 is under investigation in clinical trial NCT04731259 (Study to Evaluate the Safety of ATR-04).

  8. Drug

    LC16M8

    go.drugbank.com/drugs/DB05019
    Investigational

    LC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines. … It is the only attenuated vaccine to be licensed for use in humans to prevent smallpox infection.

  9. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. … It is being developed by Fibrex Medical Inc.

  10. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    It is considered a small-molecule prodrug. CDP323 was originally developed by the British biopharmaceutical company Celltech plc. … CDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple